A Phase 2, randomized, double-blind, placebo-controlled trial of presatovir for the treatment of respiratory syncytial virus upper respiratory tract infection in hematopoietic-cell transplant recipients - Chemaly, R F; Dadwal, S S; Bergeron, A (Clin Infect Dis, 2020)